Abstract
Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have